Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06272-4 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Rheumatology International, 2026. Verfasst von Marta Kaminska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Peptidyl-Dipeptidase A, Gingipain Cysteine Endopeptidases, Cardiovascular Diseases. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bergen.
Abstract (Originalsprache)
We assessed cross-sectional relationships of rheumatoid arthritis (RA) disease activity and cardio-metabolic comorbidities with serum peptidylarginine deiminase 4 (PAD4)-potentiating activity, domain-resolved angiotensin I converting enzyme (ACE1) enzymatic activity, and Porphyromonas gingivalis -specific antibodies. 177 RA patients and 147 healthy controls (HC) were included in the study. Clinical profiling included DAS28, CRP/ESR, treatments, and comorbidities. PAD4-potentiating activity, ACE1 activities, and anti-gingipain antibodies were measured using standardized in-house assays. Associations with RA status, treatments, and outcomes were analysed using covariate-adjusted models; discrimination for selected comorbidities was explored with ROC analyses. PAD4-potentiating activity, anti-Kgp/anti-RgpB and ACE1 activities did not differ between RA and controls. In RA, anti-Kgp showed a weak correlation with DAS28 (Rs=0.17, p=0.033) and was lower with biologic disease-modifying antirheumatic drugs (DMARDs); ACE1 activity was lower among synthetic-DMARDs users across all three substrates (all p≈0.01–0.04). None of the biomarkers showed independent associations with DAS28 in adjusted models. Overall discrimination for cardio-metabolic outcomes was limited; small, predefined strata showed exploratory signals, but low event counts and multiple comparisons constrain inference. In this cohort, between-group differences were limited overall. However, two exploratory within-RA signals emerged: anti-Kgp levels were weakly associated with disease activity and therapy, and lower ACE1 activity was associated with synthetic DMARDs use. Together, anti-Kgp and ACE1 (N-domain) may reflect mucosal-immune and vascular-remodeling axes that could relate to comorbidity patterns and warrant prospective, pre-specified validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Broegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
- Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
- Department of Rheumatology, University Hospital Cassiano Antônio Moraes - Federal University of Espírito Santo (HUCAM-UFES), Vitória, ES, Brazil.
- Małopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
- Department of Physiological Sciences, Health Sciences Center (CCS), Federal University of Espírito Santo (UFES), Vitória, ES, Brazil.
- Department of Medicine and Postgraduate Program in Public Health (PPGSC), University Hospital Cassiano Antônio Moraes - Federal University of Espírito Santo (HUCAM-UFES), Vitória, ES, Brazil.
Förderung
- University of Bergen
Zitieren
APA
Kaminska, M., Chrobak, M., Silva, L. S. A., de Oliveira, Y. G. P., Bielecka, E., Pinto, A. D., Duque, R. H., Mill, J. G., Valim, V., & Mydel, P. (2026). Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study. Rheumatology International. https://doi.org/10.1007/s00296-026-06272-4
Vancouver
Kaminska M, Chrobak M, Silva LSA, de Oliveira YGP, Bielecka E, Pinto AD, et al. Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study. Rheumatology International. 2026. doi:10.1007/s00296-026-06272-4
BibTeX
@article{Kaminska2026,
author = {Kaminska, Marta and Chrobak, Maja and Silva, Lucas Sathler Alves and de Oliveira, Yasmin Gurtler Pinheiro and Bielecka, Ewa and Pinto, Arthur Dalmaso and Duque, Ruben Horst and Mill, Jose Geraldo and Valim, Valeria and Mydel, Piotr},
title = {Anti-gingipain antibodies and ACE1 activity in rheumatoid arthritis: associations with disease activity and cardiovascular comorbidity in a cross-sectional study},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06272-4}
}
EUVIMED